TruSight Oncology 500 Portfolio

TruSight Oncology 500 portfolio

The TruSight Oncology 500 portfolio consists of three research assays which enable pan-cancer comprehensive genomic profiling (CGP) for solid tumors from either blood or tissue biopsy samples. The portfolio is designed to identify relevant biomarkers in guidelines and clinical research, such as tumor mutational burden (TMB), microsatellite instability (MSI), and homologous recombination deficiency (HRD).

TruSight Oncology 500 Assay

Now with HRD* *Not available in Japan

Assess relevant DNA and RNA cancer biomarkers from FFPE tumor tissue, now including HRD through an accessory kit to assess the Genomic Instability Score (GIS).

TruSight Oncology 500 High-Throughput Assay

Now offered on NextSeq 1000, NextSeq 2000
and NovaSeq X Series

Batch up to 960 samples at a time while using the same panel content and tissue input type as the TruSight Oncology 500 assay.

TruSight Oncology 500 ctDNA v2 Assay

Now offered on NovaSeq X Series

Analyze circulating tumor DNA (ctDNA) from blood plasma with a more sensitive and streamlined assay in <4 days with automation-friendly options.

Benefits of TruSight Oncology 500 portfolio

Enable comprehensive genomic profiling

Bring the assay into your lab

Integrated, flexible, and scalable workflow

Achieve timely and reliable results

TruSight Oncology 500 portfolio news

Learn about portfolio updates that enable a simpler, faster, and more scalable samples-to-results workflow to enable comprehensive genomic profiling in your lab.

HRD assessment

Maximize tumor insights by enabling comprehensive genomic profiling with the added value of homologous recombination deficiency (HRD) assessment. HRD is available for TruSight Oncology 500^*.

^*Not available in Japan

Improved ctDNA assessment with next gen assay

TruSight Oncology 500 ctDNA v2 brings more sensitive ctDNA analysis from blood with advanced chemistry to offer a more streamlined sample-to-answer workflow in <4 days.

End-to-end solutions for bioinformatics

From wet lab to data insights, Illumina Connected Software offers solutions for every workflow stage of the TruSight Oncology 500 portfolio.

NovaSeq X Series now supported

TruSight Oncology 500 High-Throughput and ctDNA v2 are fully supported on the NovaSeq X Series with the same great performance as the NovaSeq 6000.

Assay comparison

TruSight Oncology 500	TruSight Oncology 500 High-Throughput	TruSight Oncology 500 ctDNA v2
FFPE (DNA and RNA)	FFPE (DNA and RNA)	Blood (cfDNA)
523 genes for DNA variants	523 genes for DNA variants	523 genes for DNA variants
55 genes for RNA fusions and splice variants	55 genes for RNA fusions and splice variants	23 genes for DNA fusions
Variants called: SNVs InDels CNVs Fusions Splice variants Genomic signatures TMB (Immuno-Oncology) MSI (Immuno-Oncology) HRD - Through addition of TSO 500 HRD kit	Variants called: SNVs InDels CNVs Fusions Splice variants Genomic signatures TMB (Immuno-Oncology) MSI (Immuno-Oncology)	Variants called: SNVs InDels CNVs Fusions (from DNA) Genomic signatures TMB (Immuno-Oncology) MSI (Immuno-Oncology)
Panel size: 1.94 Mb DNA; 358 kb RNA	Panel size: 1.94 Mb DNA; 358 kb RNA	Panel size: 1.94 Mb DNA
Approximate Turnaround Time: 4–5 days	Approximate Turnaround Time: 4–5 days	Approximate Turnaround Time: 3-4 days
Sequencing Platforms: TSO 500 -- NextSeq 500, NextSeq 550, NextSeq550Dx in Research Mode TSO 500 HRD -- NextSeq 550, NextSeq 550Dx in Research Mode, NovaSeq 6000 SP Flow Cell	Sequencing Platforms: NextSeq 1000 & 2000^a NovaSeq 6000 NovaSeq 6000Dx in RUO Mode ^a NovaSeq X Series^a	Sequencing Platforms: NovaSeq 6000 NovaSeq 6000Dx in RUO Mode ^a NovaSeq X
Sample Batching: TSO 500 -- 8 samples/run TSO 500 HRD -- 8-16 samples/run	Sample Batching: 8-36 samples/run (NextSeq 1000 & 2000) 16–192 samples/run (NovaSeq 6000) 32-480 samples/run (NovaSeq X) 32-960 samples/run (NovaSeq X Plus)	Sample Batching: 8–48 samples/run
Sample input: 40 ng DNA 40 ng RNA	Sample input: 40 ng DNA 40–80 ng RNA	Sample input: 20 ng cfDNA (10–30 ng possible)
Analytical Specificity: 99.9998%	Analytical Specificity: 99.9998%	Analytical Specificity: 99.9994% (SNVs)
Analytical Sensitivity: >96%	Analytical Sensitivity: >96%	Analytical Sensitivity: >95%

^aRequires a separate, stand-alone DRAGEN server for secondary analysis

Pan-cancer biomarkers

Detection of currently relevant DNA & RNA^* variants for multiple types of solid tumors. Some key biomarkers include:

Pan-cancer: BRAFNTRK1 NTRK2 NTRK3RET MSI TMB
Genes with biomarkers of significance^†										Genes with biomarkers of potential significance^‡
Breast	BRCA1	BRCA2	ERBB2	ESR1	PALB2	PIK3CA				180
Colorectal	ERBB2	KRAS	NRAS							166
Bone	EGFR	ERG	ETV1	ETV4	EWSR1	FEV	FLI1	FUS	H3F3A	140
Bone	HEY1	IDH1	MDM2	NCOA2	SMARCB1					140
Lung	ALK	EGFR	ERBB2	KRAS	MET	NUTM1	ROS1			223
Melanoma	KIT	NRAS	ROS1							172
Ovarian	BRCA1	BRCA2	FOXL2							149
CNS	APC	ATRX	CDKN2A	CDKN2B	EGFR	H3F3A	HIST1H3B	HIST1H3C	IDH1	140
CNS	IDH2	MYCN	PTCH1	RELA	TERT	TP53				140
Prostate	AR	ATM	BARD1	BRCA1	BRCA2	BRIP1	CDK12	CHEK1	CHEK2	151
Prostate	FANCL	FGFR2	FGFR3	PALB2	RAD51B	RAD51C	RAD51D	RAD54L		151
Thyroid	HRAS	KRAS	NRAS	RET	TERT					165
Uterine & cervical	BRCA2	EPC1	ERBB2	ESR1	FOXO1	GREB1	JAZF1	NCOA2	NCOA3	138
	NUTM2A	NUTM2B	PAX3	PAX7	PHF1	POLE	SMARCA4	SUZ12	TP53
	YWHAE
Other Solid Tumors	ALK	APC	ARID1A	ASPSCR1	ATF1	ATIC	BAP1	BCOR	BRCA1	152
	BRCA2	CAMTA1	CARS	CCNB2	CDK4	CDKN2A	CIC	CITED2	CLTC
	COL1A1	COL6A3	CREB1	CREB3L1	CREB3L2	CSF1	CTNNB1	DDIT3	DDX3X
	DNAJB1	DUX4	EED	EGFR	ERBB2	ERG	ETV1	ETV4	ETV6

	EWSR1	FEV	FGFR2	FGFR3	FLI1	FOXL2	FOXO1	FOXO4	FUS
	GLI1	HEY1	HGF	HMGA2	IDH1	KRAS	LEUTX	MAML3	MDM2
	MYB	MYOD1	NAB2	NCOA2	NF1	NFATC2	NFIB	NR4A3	NRAS
	NUTMI	NUTM2A	NUTM2B	PALB2	PATZ1	PAX3	PAX7	PDGFB	PDGFRA
	PRKACA	PRKD1	RANBP2	ROS1	SDHA	SDHB	SDHC	SDHD	SMARCB1
	SS18	SSX1	SSX2	SSX4	STAT6	SUZ12	TAF15	TCF12	TERT
	TFE3	TFEB	TFG	TP53	TPM3	TPM4	TRAF7	TSPAN31	VGLL2
	WT1	WWTR1	YAP1	YWHAE	ZC3H7B

The genes and biomarkers listed in this table are a subset of all genes included in the panel. To see the full gene list, view the product datasheet, available under Product Literature on the respective product pages.

^* RNA variants only called from TSO 500 and TSO 500 HT assays.

^† The product to evaluate DNA & RNA variants is the TruSight Oncology 500 DNA/RNA Bundle.

Featured NGS workflows

Prepare library

TruSight Oncology 500 ctDNA v2 Assay

Sequence

NovaSeq 6000 System

NovaSeq 6000 Dx System^* (in RUO mode)

NovaSeq X System^†

Analyze

Variant Calling

Local analysis via DRAGEN server

Cloud analysis via Illumina Connected Analytics (ICA)

Insights and report generation

Illumina Connected Insights product line^‡

Velsera Clinical Genomics Workspace Software

Prepare Library

TruSight Oncology 500 Assay

Sequence

NextSeq 550 System

NextSeq 550Dx in RUO Mode

Analyze

Variant Calling

DRAGEN Bio-IT Platform: on-premise via DRAGEN server

DRAGEN Bio-IT Platform: cloud-based via Illumina Connected Analytics (ICA)

TruSight Oncology 500 Local App: Docker-based Software

Local Run Manager: On-instrument Software

Insights and report generation

Illumina Connected Insights product line^‡

Velsera Clinical Genomics Workspace Software

Prepare Library

TruSight Oncology 500 High-Throughput

Sequence

NextSeq 1000 and 2000 System

NovaSeq 6000 System

NovaSeq 6000Dx System (in research mode)

NovaSeq X System

Analyze

Variant Calling

DRAGEN Bio-IT Platform: on-premise via DRAGEN server

DRAGEN Bio-IT Platform: cloud-based via Illumina Connected Analytics (ICA)

TruSight Oncology 500 Local App: Docker-based Software

Insights and report generation

Illumina Connected Insights product line^‡

Velsera Clinical Genomics Workspace Software

^*Assay compatibility available in 2024.

^† Only for TSO 500 ctDNA v2 and TSO 500 HT.

^‡ Not available in all countries. Illumina Connected Insights supports user-defined tertiary analysis through API calls to third-party knowledge sources.

TruSight Oncology 500 portfolio resources

TruSight Oncology ctDNA 500 v2

Illumina has improved the analysis of solid tumors from circulating tumor DNA (ctDNA) with TruSight Oncology 500 ctDNA v2. Learn about the new features and benefits in the video.

Research collaboration with Nation Center Japan

TruSight Oncology 500 ctDNA panel to be used for research into personalized cancer treatments for nasopharyngeal carcinoma.

Illumina partners to advance precision medicine for late-stage cancer patients

CELIA research study will assess value of CGP with the Illumina TruSight Oncology 500 assay versus standard of care in the French health care system.

TruSight Oncology 500 HRD

Homologous recombination deficiency (HRD) is an important biomarker in ovarian cancer. Hear about TSO 500 HRD assay performance from Dr. Guillaume Bataillon at the Oncopole Toulouse laboratory in France.

For every lab, everywhere

NextSeq 1000 and NextSeq 2000 Reagents

NGS Workflow Finder

DRAGEN v4.3 now available on-premises and on-cloud

Illumina Proactive Instrument Performance Service

Do more, faster than ever

Next-generation sequencing for beginners

Next-generation sequencing for beginners

Next-generation sequencing for beginners

Next-generation sequencing for beginners

Next-generation sequencing for beginners

Next-generation sequencing for beginners

Next-generation sequencing for beginners

Celebrate DNA Day with Your Students

Celebrate DNA Day with Your Students

Celebrate DNA Day with Your Students

Celebrate DNA Day with Your Students

Celebrate DNA Day with Your Students

Celebrate DNA Day with Your Students

Celebrate DNA Day with Your Students

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

TruSight Oncology 500 Portfolio

Take cancer from uncertainty to insight

TruSight Oncology 500 portfolio

TruSight Oncology 500 Assay

TruSight Oncology 500 High-Throughput Assay

TruSight Oncology 500 ctDNA v2 Assay

Benefits of TruSight Oncology 500 portfolio

Enable comprehensive genomic profiling

Bring the assay into your lab

Integrated, flexible, and scalable workflow

Achieve timely and reliable results

TruSight Oncology 500 portfolio brochure

TruSight Oncology 500 portfolio news

HRD assessment

Improved ctDNA assessment with next gen assay

End-to-end solutions for bioinformatics

NovaSeq X Series now supported

Detection of currently relevant DNA & RNA^* variants for multiple types of solid tumors. Some key biomarkers include: